LOS ANGELES (MarketWatch) -- Amgen Inc. late Thursday said the U.S. Food and Drug Administration has approved its denosumab drug for the prevention and reduction of bone complications in cancer patients with solid tumors. Amgen plans to sell the drug under the Xgeva name. Denosumab marketed under the Prolia brand at a lower dose is already used to treat post-menopausal osteoporosis. Xgeva is the ...